Systemic administration of a potent mouse monoclonal antibody provides multisite protection against HPV16 infection
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.113272 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Bilian Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Public Health Research, Medical School, Nanjing University, Nanjing, China. Hauptthemen laut MEDLINE: Papillomavirus Infections, Human papillomavirus 16, Antibodies, Neutralizing, Antibodies, Viral. Die Arbeit nennt 47 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Although preventive vaccines for Human Papillomaviruses (HPV) are available, a definitive cure for the viral infection itself is currently lacking. There is a sizable population that remains inaccessible to HPV vaccination due to reasons such as high costs or lack of availability of the vaccines. Therefore, there remains a significant population susceptible to HPV infection. Persistent multisite infections with high-risk HPV types can cause cancer at several different anatomic sites.Especially HPV16 is a key etiologic factor for cervical, other ano-genital and oropharyngeal cancers. Therefore, it is imperative to develop pharmaceutical interventions for the treatment of viral infections. In this study, a panel of 9 neutralizing antibodies was screened using the hybridoma technique, with 20F6 being identified as the representative antibody. The purified 20F6 exhibited an IC50 of 0.0011 μg/ml against HPV16, demonstrating potent viral inhibitory activity. Moreover, it displayed cross-neutralizing efficacy towards other Alphapapillom 9 subtypes including HPV31, HPV33, HPV52, and HPV58 with respective IC50 values of 2.0 μg/ml, 7.3 μg/ml, 1.7 μg/ml, and 3.0 μg/ml. 20F6 recognizes the linear epitope MSLW, the first four amino-acids located at the very N-terminus of the HPV16 L1 protein. Administration of 20F6, 24 h prior to and following HPV16 pseudo-virion (PSV) challenge, conferred protection against infection in mice at doses as low as 1 mg/kg. Following intraperitoneal administration of 20F6, neutralizing antibodies were consistently detected at both oral and vaginal sites, indicating that prophylactic systemic administration of 20F6 may confer efficient protection against multiple susceptible mucosal sites.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Public Health Research, Medical School, Nanjing University, Nanjing, China.
- Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
- Yancheng Clinical College, Xuzhou Medical University, Yancheng, China.
- School of Life Sciences, Ningxia University, Yinchuan, China.
- Yancheng Clinical College, Xuzhou Medical University, Yancheng, China. Electronic address: cxp_ycyy@126.com.
- Nanjing International Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Huang, B., Zhang, D., Wang, H., Li, S., Guo, J., Cui, S., Chen, X., Hong, Y., & Wu, Z. (2024). Systemic administration of a potent mouse monoclonal antibody provides multisite protection against HPV16 infection. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.113272
Vancouver
Huang B, Zhang D, Wang H, Li S, Guo J, Cui S, et al. Systemic administration of a potent mouse monoclonal antibody provides multisite protection against HPV16 infection. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.113272
BibTeX
@article{Huang2024,
author = {Huang, Bilian and Zhang, Doudou and Wang, Hongyun and Li, Siyu and Guo, Jianjun and Cui, Shengwei and Chen, Xiaoping and Hong, Ying and Wu, Zhiwei},
title = {Systemic administration of a potent mouse monoclonal antibody provides multisite protection against HPV16 infection},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.113272}
}
EUVIMED